News Column

Batu Biologics Launches Crowdfunding Campaign to Complete Preclinical Testing for VallovaxTM Cancer Therapy

July 2, 2014

By a News Reporter-Staff News Editor at Biotech Week -- Batu Biologics announced the launch of its first crowdfunding campaign with Indiegogo seeking to raise $100,000 dollars to complete preclinical testing for VallovaxTM, an immunotherapeutic product which selectively kills blood vessels feeding the tumor (see also Batu Biologics).

Individuals seeking to contribute may do so at: ValloVax™ combats cancer by training the immune system to selectively target the blood vessels of the tumor, or the tumor endothelium, preventing the sustainable growth and proliferation of neoplastic cells.

Batu's strategy is focused on preparing ValloVax™ to enter Phase I clinical trials. Batu Biologics is targeting lung cancer as the first treatment indication for ValloVax™ with expanded indications to follow.

"Batu Biologics is extremely excited to leverage crowdfunding platforms that make contributions to scientific progress easily accessible and understandable to the community," commented Samuel C. Wagner, President and CEO of Batu Biologics. "We hope to utilize this crowdfunding campaign as a stepping stone toward larger future campaigns. Batu hopes to not only progress the science behind its anti-angiogenic cancer vaccine, VallovaxTM, but to also capitalize on the non-dilutive investment and support from the surrounding community." About Batu Biologics: Batu Biologics is a preclinical biopharmaceutical company focusing on developing and commercializing allogeneic cell therapies in the area of immune modulation. Our products are centered around the idea of creating or breaking immune tolerance. The company is currently in the preclinical stages of drug development for its two flagship products: Immstem and Vallovax. Batu Biologics has filed two provisional patents in the field of cancer immunotherapy and plans to significantly expand its IP in 2014. Recently, Batu Biologics published in the peer reviewed literature with Dr. Francesco Marincola, President of the Society for Immunotherapy of Cancer, as well as several other internationally-renowned immunotherapists, a novel method of decreasing toxicity of immunotherapy Corporate Address:9255 Towne Centre DriveSuite 450San Diego, CA 92121 Laboratory Address:Janssen Research and Development3210 Merryfield RowSan Diego, CA 92121

Keywords for this news article include: Biotechnology, Oncology, Immunotherapy, Batu Biologics, Cancer Vaccines, Immunomodulation, Pre-Trial Research, Biological Products, Clinical Trials and Studies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters